Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.41 |
| ▸ | FDPS | P14324 | 9/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608808 | 1.00 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL50029 | 1.00 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL51185 | 1.00 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL971499 | 1.00 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL3624293 | 1.00 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL10931906 | 1.00 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL23034285 | 1.00 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL3625459 | 1.00 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL8622066 | 1.00 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL21128 | 1.00 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4279527-A1 | BIODEGRADABLE POLYESTER RESIN COMPOSITION | Ecovance Co. Ltd (KR) | 2023-11-22 | — | — | EP | disclosed |
| EP-3140308-B1 | PROCESS FOR THE PREPARATION OF OPIOID COMPOUNDS | NORAMCO LLC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-9701687-B2 | Process for the preparation of opioid compounds | NORAMCO, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701688-B2 | Process for the preparation of opioid compounds | NORAMCO, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| EP-3140307-A2 | PROCESS FOR THE PREPARATION OF OPIOID COMPOUNDS | Noramco, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-3140308-A2 | PROCESS FOR THE PREPARATION OF OPIOID COMPOUNDS | Noramco, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015171354-A2 | PROCESS FOR THE PREPARATION OF OPIOID COMPOUNDS | NORAMCO, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015171353-A2 | PROCESS FOR THE PREPARATION OF OPIOID COMPOUNDS | NORAMCO, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315204-A1 | PROCESS FOR THE PREPARATION OF OPIOID COMPOUNDS | NORAMCO, LLC (FORMERLY KNOWN AS NORAMCO, INC.) | 2015-11-05 | — | — | US | disclosed |
| US-20150315205-A1 | PROCESS FOR THE PREPARATION OF OPIOID COMPOUNDS | NORAMCO, LLC (FORMERLY KNOWN AS NORAMCO, INC.) | 2015-11-05 | — | — | US | disclosed |
| US-5705085-A | DURABILITY, REDUCED THICKENING; BRAKES, CLUTCHES | LORD CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1997048110-A1 | MAGNETORHEOLOGICAL FLUID | LORD CORPORATION (US) | 1997-12-18 | — | — | WO | disclosed |
| WO-1997048109-A1 | ORGANOMOLYBDENUM-CONTAINING MAGNETORHEOLOGICAL FLUID | LORD CORPORATION (US) | 1997-12-18 | — | — | WO | disclosed |
| US-5683615-A | Magnetorheological fluid | LORD CORPORATION (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0276497-B1 | PROCESS FOR THE PRODUCTION OF MULTIPLE RADIOGRAPHIC IMAGES | AGFA-GEVAERT N.V. (BE) | 1991-10-09 | — | — | EP | disclosed |
| US-4893021-A | Exposure of multiple photosensitive layers; of fluorescent material and visible light reflectors | AGFA-GEVAERT, N.V. (BE) | 1990-01-09 | — | — | US | disclosed |
| EP-0276497-A1 | Process for the production of multiple radiographic images | AGFA-GEVAERT N.V. (BE) | 1988-08-03 | — | — | EP | disclosed |
| US-4177071-A | HIGH SENSITIVITY TO PENTRATING RADIATION; INSENSITIVE TO FORMATION OF PRESSURE MARKS | AGFA-GEVAERT, N.V. (BE) | 1979-12-04 | — | — | US | disclosed |
| US-4130429-A | X*RAY FLUORESCENT SCREEN, SILVER HALIDE | AGFA-GEVAERT, N.V. (BE) | 1978-12-19 | — | — | US | disclosed |
| US-4130428-A | FLUORESCENT SCREEN | AGFA-GEVAERT, N.V. (BE) | 1978-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315205-A1 | PROCESS FOR THE PREPARATION OF OPIOID COMPOUNDS | OPRK1, OPRL1, OPRM1 | TSHR 3669/4885THRB 553/4885GGPS1 4366/4885 |
| US-20150315204-A1 | PROCESS FOR THE PREPARATION OF OPIOID COMPOUNDS | OPRK1, OPRL1, OPRM1 | TSHR 3669/4885THRB 553/4885GGPS1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.